AIM ImmunoTech Inc (STU:HXB2)

€ 0.356 0.002 (0.56%) Market Cap: 18.26 Mil Enterprise Value: 11.88 Mil PE Ratio: 0 PB Ratio: 4.70 GF Score: 40/100

Q1 2024 AIM ImmunoTech Inc Earnings Call Transcript
May 16, 2024

€0.364 (+0.55%)

Earnings
Q4 2023 AIM ImmunoTech Inc Earnings Call Transcript
Apr 02, 2024

€0.452 (+5.12%)

Earnings
AIM ImmunoTech Inc at HC Wainwright Investment Conference - New York Transcript
Sep 11, 2023
Q2 2023 AIM ImmunoTech Inc Earnings Call Transcript
Aug 15, 2023

€0.57 (+7.55%)

Earnings
AIM ImmunoTech Inc Investor Summer Spotlight Series Transcript
Jul 12, 2023
Q1 2023 AIM ImmunoTech Inc Earnings Call Transcript
May 16, 2023

€0.372 (-6.53%)

Earnings
Q4 2022 AIM ImmunoTech Inc Earnings Call Transcript
Apr 03, 2023

€0.39 (+1.38%)

Earnings
AIM ImmunoTech Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Sep 12, 2022
AIM ImmunoTech Inc at JTC Team Top Picks Virtual Investor Conference Transcript
Jan 26, 2022
AIM ImmunoTech Inc at SNN Network Virtual Conference Transcript
Aug 03, 2020
AIM ImmunoTech on Commercial Launch in Argentina for Chronic Fatigue and COVID-19 Clinical Trials- Corporate Analyst Meeting Transcript
Jul 31, 2020
CEO Roadshow Interview: Thomas Equels, CEO of AIM Immunotech Corporate Analyst Meeting Transcript
Jun 24, 2020
AIM ImmunoTech greenlit to import chronic fatigue syndrome drug into Argentina Corporate Analyst Meeting Transcript
Jun 22, 2020
AIM ImmunoTech Inc To Describe Their Approach and Progress with Ampligen to Combat COVID-19 Transcript
May 28, 2020
AIM ImmunoTech Inc at SNN Planet MicroCap Showcase Transcript
Apr 22, 2020

CEO Roadshow Interview: Thomas Equels, CEO of AIM Immunotech Corporate Analyst Meeting Transcript

Jun 24, 2020 / NTS GMT

Release Date Price: €2 (+1.52%)

Transcript

Mike Elliott

CEO Roadshow - Moderator

Hi, I am Mike Elliott and you're watching CEO Roadshow. Today, we're joined by Mr. Thomas Equels, he is CEO of AIM Immunotec, an immuno pharma company, focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers. They trade under the ticker AIM. Good morning, Tom. Great to have you back on the show.

Thomas Equels

AIM Immunotec, Inc. - Vice Chairman, President, CEO

Good to be here, Mike, pleasure to see you again.

Mike Elliott

CEO Roadshow - Moderator

So I first, can you just tell us -- let's start off by your -- with your latest news, which came out last week regarding FDA authorization for the first human trial assessing the safety and effectiveness of Ampligen in cancer patients with COVID-19. Tell us more about that.

Thomas Equels

AIM Immunotec, Inc. - Vice Chairman, President, CEO

Well, we're very excited about that because we have established a strong position

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.